Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Other

Mochida Seiyaku Kabushiki Kaisha

Sanwa Kosan Kabushiki Kaisha

Masakazu Mitsuhashi

Toshio Miyake

Masashi Kurimoto

Shuzo Sakai

Hiroto Chaen

Shunsaku Koyama

Satoshi Iritani

Mitsuko Usui

Hiromi Hijiya

Tyoku Matsuhashi

Shunsaku Ando

Kenta Shiga

Satoshi Kikuchi

Osamu Matsuda

Haruo Ohnishi

Yoshiaki Sone

Akira Misaki

Yoshikatsu Miwa

Zenichi Yoshino

Yoko Hirashima

Hitoshi Yui

Toshi Miyake

Shigemitsu Ohsaki

Yoshiki Kurahashi

Toshiaki Komaki

Hiromasa Ueyama

Hitoshi Murasaki

Takatoshi Tamura

Akio Yamamoto

Makoto Kittaka

Tyoku Matuhashi

A method for converting directory data is executed to selectively reflect any entry of the directory data onto application data. The directory data converting method includes the steps of searching from the directory data the data of the directory entry specified by a filtering rule corresponding to the application data; converting the searched directory entry data according to the schema conversion rule compatible with the filtering rule used for searching the data; and reflecting the schema-converted entry data onto said application data.

Method for converting directory data, and program and device therefor

A method for improving the aftertaste of sucrose without lowering the sweetening power of sucrose, which comprises incorporating trehalose into sucrose in an amount of 2-12% to the sucrose, on a dry solid basis. The method produces saccharide compositions and food products having improved aftertaste of sucrose without lowering the sweetening power of sucrose.

Method and composition for improving the aftertaste of sucrose

Disclosed herein is a continuous manufacturing method for anhydrous crystalline maltitol comprising the following steps: (i) a heating and concentrating step where an aqueous solution containing maltitol in which maltitol is a main ingredient is continuously heated and concentrated to give a concentrated solution having a high concentration; (ii) a seed crystal adding and mixing step where the seed crystals are added to and mixed with the above concentrated solution with heating to give a massceuite containing the seed crystals; and (iii) a crystal aging step where the massceuite is subjected to disintegration, mixing, stirring and transfer in an atmosphere in which temperature and moisture are adjusted to proceed the crystallization.

Method for the continuous manufacture of anhydrous crystalline maltitol

A method using a therapeutic agent for cat respiratory diseases which contains a human interferon as an effective ingredient. The therapeutic agent exerts a strong efficacy on cats with only a small dose even if administered to them orally or parenterally, and reduces the labor and burden of veterinaries and cat owners by a large margin.

Therapeutic agent for cat respiratory diseases and method of treatment

A human myelomonocyte interferon-gamma having a novel polypeptide and carbohydrate chain structure is produced by propagation of an established human myelomonocyte in vitro or after being implanted in a non-human warm-blooded animal or in a diffusion chamber placed inside or outside the body of the animal. The human myelomonocyte may be contacted with an inducer during propagation. A monoclonal antibody specific to the human myelomonocyte interferon-gamma is produced by immunizing a non-human warm-blooded animal with purified human myelomonocyte interferon-gamma as an antigen, recovering an antibody producing cell from the animal and fusing the cell with a myeloma cell to produce a hybrid capable of producing the monoclonal antibody. The human myelomonocyte interferon-gamma can be purified by chromatography with an immobilized anti-human myelomonocyte interferon-gamma antibody such as the monoclonal antibody. The human myelomonocyte interferon-gamma can be used as a prophylactic and therapeutic agent for human interferon-gamma susceptive diseases.

Purification of human myelomonocyte interferon gamma with an immobilized

Disclosed is an alkali-treated bagasse prepared by softening a bagasse with calcium oxide together with or without sodium hydroxide while preventing the substantial decomposition of cellulose and hemicellulose, a bagasse feed and a fermented bagasse feed prepared from the alkali-treated bagasse, and their preparations and uses as well as bacteria for fermenting the alkali-treated bagasse. These bagasse and bagasse feeds save sugar-refinery industries from the difficulties to treat bagasse deemed as an unutilized industrial waste, and livestock farming industries from the shortage of roughage, and further is extremely significant in agriculture, industries of sweetening products, feed industries and livestock product processors. A bacterium strain particularly useful for the fermentation is Enterococcus faecium FERM BP-4504.

Biologically pure strain of Enterococcus falcium FERM BP-4504

A human myelomonocyte interferon-gamma having a novel polypeptide and carbohydrate chain structure is produced by propagation of an established human myelomonocyte in vitro or after being implanted in a non-human warm-blooded animal or in a diffusion chamber placed inside or outside the body of the animal. The human myelomonocyte may be contacted with an inducer during propagation. A monoclonal antibody specific to the human myelomonocyte interferon-gamma is produced by immunizing a non-human warm-blooded animal with purified human myelomonocyte interferon-gamma as an antigen, recovering an antibody producing cell from the animal and fusing the cell with a myeloma cell to produce a hybrid capable of producing the monoclonal antibody. The human myelomonocyte interferon-gamma can be purified by chromatography with an anti-human myelomonocyte interferon-gamma antibody such as the monoclonal antibody. The human myelomonocyte interferon-gamma can be used as a prophylactic and therapeutic agent for human interferon-gamma susceptive diseases.

Preparation of a monoclonal antibody specific to human myelomonocyte

A highly-digestible, preferred taste and high-quality fermented bagasse feed prepared by incorporating a lactic acid bacterium capable of proliferating in an alkaline nutrient culture medium of not less than pH 9.5 or in a nutrient culture medium containing sodium chloride of 6.5 w/w % into an alkali-treated bagasse which is prepared by softening a bagasse while preventing the substantial decomposition of cellulose and hemicellulose, and succeedingly fermenting the resultant mixture, and to its preparation and uses.

Fermented bagasse feed, and its preparation and uses

An alkali-treated bagasse is prepared by softening a bagasse with calcium oxide together with or without sodium hydroxide while preventing the substantial decomposition of cellulose and hemicellulose, a bagasse feed and a fermented bagasse feed prepared from the alkali-treated bagasse, and their preparations and uses as well as bacteria for fermenting the alkali-treated bagasse.

Alkali-treated bagasse, and its preparation and uses

The present invention relates to a novel human interferon-gamma derived from an established human myelomonocyte, a process to prepare said interferon-gamma, and its use. The human myelomonocyte interferon-gamma has a novel polypeptide and carbohydrate chain structure, and it is effective in preventing and treating viral diseases, malignant tumors and immunopathies alone or in combination with other lymphokine and/or chemotherapeutic. The human myelomonocyte interferon-gamma may be produced by culturing an established human myelomonocyte on a culture medium in vitro. Alternatively, an established human myelomonocyte is implanted in a non-human warm-blooded animal or in a diffusion chamber placed inside or outside the body of the animal, and then allowed to proliferate while receiving nutrient body fluid from the animal. The human myelomonocyte may be contacted with an inducer during propagation.

Preparation of human myelomonocyte interferon-gamma

Disclosed is a lighting device to emit a light which substantially does not delay the latency of P100 wave in human VEP. Such a light hardly causes eyestrain when used in illumination. This renders the lighting device very useful in various illuminations directed to retaining healthy eyes.

Method for emitting light which does not substantially delay the latency

The present invention relates to a novel human interferon-gamma derived from an established human myelomonocyte, a process to prepare said interferon-gamma, and its use. The human myelomonocyte interferon-gamma has a novel polypeptide and carbohydrate chain structure, and it is effective in preventing and treating viral diseases, malignant tumors and immunopathies alone or in combination with other lymphokine and/or chemotherapeutic.

Human myelomonocyte interferon-gamma, and process for preparation and

An additive for aquaculture feed for fish and shellfish, which contains L-ascorbic acid-2-glucoside as an active ingredient, an aquaculture feed for fish and shellfish containing said additive, and an aquaculture feed for fish and shellfish, which has been added with said additive and granulated. The additive for feed of the present invention, namely, L-ascorbic acid-2-glucoside 1) does not have reducing ability by itself, and extremely stable, 2) can be decomposed into L-ascorbic acid and D-glucose when taken in fish and shellfish, and can exhibit physiological effects inherent to L-ascorbic acid, and 3) is greatly improved in heat resistance and light resistance in comparison with L-ascorbic acid, and shows markedly small loss of L-ascorbic acid activity during the production and storage of feed.

Additive for aquaculture feed for fish and shellfish and aquaculture

A novel hyposensitization agent was prepared by covalently attaching a saccharide to a cedar pollen allergen having a partial amino acid sequence of Ala-Ile-Asn-Ile-Phe-Asn- beginning at its N-terminal. The hyposensitization agent, when compared with an intact cedar pollen allergen, extremely accelerates the production of immunoglobulin G and M antibodies which are specific to intact cedar pollen allergen, but extremely reduces the production of immunoglobulin E antibody which is specific to the allergen. Thus, the hyposensitization agent is administrable to cedar pollinosis patients with no anaphylaxis and allergy, and cuts hyposensitization period to about 1/3 to 1/200.

Hyposensitization agent

A monoclonal antibody specific to the lymphokine LK 2, and its production is disclosed. The novel lymphokine LK 2 is a glycoprotein with a molecular weight of 20,000.+-.2,000 daltons; isoelectric point pI, 6.2.+-.0.3; electrophoretic mobility Rf, 0.29.+-.0.02; cytotoxic on L 929 cells; and not substantially growth inhibitive on KB cells. The lymphokine significantly inhibits the growth of malignant human tumors in vivo. The monoclonal antibody may be of IgM or IgG class, and neutralizes specifically the cytotoxic activity of the lymphokine. Combined use of LK 2 with chemotherapeutic agents such as alkylating agents, metabolic antagonists, antioncotic antibiotics and plant alkaloids enhances greatly the antioncotic effect of the chemotherapeutics.

Growing community of inventors

Okayama, Japan

Masakazu Mitsuhashi